MeiraGTx (MGTX)
| Bid | 5.5 |
| Market Cap | 486.93M |
| Revenue (ttm) | 37.58M |
| Net Income (ttm) | -166.91M |
| EPS (ttm) | -2.12 |
| PE Ratio (ttm) | -2.91 |
| Forward PE | 7.7 |
| Analyst | Buy |
| Ask | 7.19 |
| Volume | 868,490 |
| Avg. Volume (20D) | 553,348.5 |
| Open | 6.72 |
| Previous Close | 6.78 |
| Day's Range | 6.05 - 6.72 |
| 52-Week Range | 3.85 - 8.75 |
| Beta | 1.24 |
About MGTX
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical develop...
Analyst Forecast
According to 2 analyst ratings, the average rating for MGTX stock is "Buy." The 12-month stock price forecast is $24.5, which is an increase of 296.76% from the latest price.
Stock Forecasts
2 months ago · seekingalpha.com
MeiraGTx: 2 Possible Near-Term BLA Filings Could Ignite Shareholder ValueMeiraGTx Holdings plc is advancing AAV-AIPL1 for AIPL1-associated Leber congenital amaurosis 4, with a near-term BLA filing in the UK under Exceptional Circumstance possible. Bota-vec, developed with ...